Business, energy, technology, markets and global industry news from Business News Today

overactive bladder

PharmaDeviceNews overactive bladder
Representative image of a urologist discussing overactive bladder and benign prostatic hyperplasia treatment data with an older male patient, reflecting Sumitomo Pharma America’s AUA 2026 vibegron findings in men aged 75 and older.
Pharma & Biotech

Can vibegron strengthen Sumitomo Pharma America’s urology position after AUA 2026?

Older men with OAB and BPH remain hard to treat. Sumitomo Pharma America’s vibegron data may sharpen the next urology market test.

Read More
Representative image of a clinician reviewing an implantable neuromodulation device in a urology setting, as BlueWind Medical raises $47.8 million to accelerate commercialisation of its Revi System for urgency urinary incontinence treatment.
Medical Devices & Diagnostics

Why BlueWind Medical’s $47.8m raise matters for the next phase of UUI treatment

UUI devices have clinical momentum. BlueWind Medical’s next challenge is proving Revi can scale through access, reimbursement, and workflow adoption.

Read More